Alternatives to AQBioSim

alvaBuilder is an innovative molecular design software that facilitates the creation of new chemical structures tailored to specific user-defined criteria, including structural, physicochemical, and modeling parameters. This tool allows for the generation of entirely new molecules from the ground up or the modification of existing ones through fragment-based and rule-driven methodologies. Moreover, alvaBuilder harmonizes with QSAR/QSPR workflows, empowering users to influence the molecular generation process through predictive models, ranges of descriptors, and targeted properties. This software is particularly beneficial for medicinal chemistry, lead optimization, and virtual screening endeavors, efficiently navigating chemical space while ensuring both chemical viability and interpretability. Designed for both research and industrial purposes, alvaBuilder is an essential resource for scenarios requiring molecular generation that is transparent, controllable, and reproducible, making it a valuable asset in the field of drug discovery. By providing these capabilities, it enhances the potential for innovative solutions in chemical research and development.

AQChemSim is an innovative cloud-based platform created by SandboxAQ that utilizes Large Quantitative Models (LQMs) based on principles of physics and chemistry to transform the landscape of materials discovery and enhancement. By incorporating techniques such as Density Functional Theory (DFT), Iterative Full Configuration Interaction (iFCI), Generative AI, Bayesian Optimization, and Chemical Foundation Models, AQChemSim facilitates precise simulations of molecular and material dynamics in real-world scenarios. The platform's features allow it to forecast performance under diverse stress conditions, expedite formulation via in silico testing, and investigate eco-friendly chemical processes. Remarkably, AQChemSim has achieved notable progress in battery technology, cutting the prediction time for lithium-ion battery end-of-life by 95%, while also attaining 35 times greater accuracy with a mere fraction of the data previously required. This advancement not only streamlines research but also paves the way for more efficient and sustainable energy solutions in the future.

Promethium is an innovative platform for chemistry simulations that harnesses the power of GPUs to significantly speed up the development of drugs and materials by providing more efficient and precise quantum chemistry calculations. Specifically engineered for NVIDIA data center GPUs, such as the A100, it utilizes advanced QC Ware streaming algorithms to deliver remarkable computational speed and impressive power efficiency. This platform can perform density functional theory (DFT) calculations on molecular systems containing as many as 2,000 atoms, enabling researchers to conduct simulations of large molecular structures that traditional CPU-based ab initio methods cannot handle. For example, it can execute a single-point calculation for a protein with 2,056 atoms in just 14 hours using only one GPU. Promethium is equipped with a diverse array of functionalities, including single-point energy computations, geometry optimizations, conformer searches, torsion scans, reaction path optimizations, transition state optimizations, interaction energy evaluations, and relaxed potential energy surface explorations. Its capabilities make it a powerful tool for chemists looking to push the boundaries of molecular modeling and simulation. Ultimately, Promethium is set to transform the landscape of computational chemistry.

Alchemite specializes in AI-enhanced physical modeling and offers solutions that assist organizations in deriving actionable insights from both experimental and simulation data, merging machine learning techniques with physics-informed models to enhance prediction accuracy, decrease experimental expenses, and streamline product and process development. Their offerings encompass a variety of domains, including materials discovery and design, predictive modeling for performance and reliability, multiscale modeling that bridges atomic and macroscopic behavior, as well as the automation of various workflow tasks such as data integration, surrogate modeling, and model validation. Furthermore, they advocate for physics-aware neural networks and hybrid modeling strategies that adhere to fundamental scientific principles while simultaneously learning from data, leading to quicker and more precise simulations, a diminished need for costly physical testing, and better-informed decision-making processes. Intellegens' tools find applications in various fields, including the prediction of battery performance and optimization of chemical processes, showcasing their versatility and effectiveness in addressing complex challenges. By integrating advanced computational methodologies, Alchemite aims to empower organizations to innovate and achieve their goals more efficiently.

BIOVIA Materials Studio serves as an all-encompassing platform for modeling and simulation, specifically tailored to assist researchers in the fields of materials science and chemistry in forecasting and comprehending how a material's atomic and molecular configurations correlate with its characteristics and functionalities. By adopting an "in silico first" strategy, researchers can enhance material performance in a budget-friendly virtual environment before moving to physical experimentation. This versatile software accommodates a diverse array of materials, such as catalysts, polymers, composites, metals, alloys, pharmaceuticals, and batteries. With capabilities that span quantum, atomistic, mesoscale, statistical, analytical, and crystallization simulations, it streamlines the development of innovative materials across multiple sectors. Additionally, its features promote rapid innovation, decrease research and development expenditures through virtual screening, and boost productivity by automating established practices within Pipeline Pilot, making it an indispensable tool for modern material research and development. This comprehensive functionality not only enhances research efficiency but also positions users at the forefront of material advancements.

Revolutionize the fields of drug discovery and materials research through cutting-edge molecular modeling techniques. Our computational platform, grounded in physics, combines unique solutions for predictive modeling, data analysis, and collaboration, facilitating swift navigation of chemical space. This innovative platform is employed by leading industries globally, serving both drug discovery initiatives and materials science applications across various sectors including aerospace, energy, semiconductors, and electronic displays. It drives our internal drug discovery projects, overseeing processes from target identification through hit discovery and lead optimization. Additionally, it enhances our collaborative research efforts aimed at creating groundbreaking medicines to address significant public health challenges. With a dedicated team of over 150 Ph.D. scientists, we commit substantial resources to research and development. Our contributions to the scientific community include more than 400 peer-reviewed publications that validate the efficacy of our physics-based methodologies, and we remain at the forefront of advancing computational modeling techniques. We are steadfast in our mission to innovate and expand the possibilities within our field.

The biopharmaceutical sector today is characterized by its intricacy, driven by increasing demands for enhanced specificity and safety, the emergence of new treatment classes, and the complexity of disease mechanisms. To navigate this intricate landscape, a profound comprehension of therapeutic dynamics is essential. Advanced modeling and simulation techniques offer a distinctive approach to investigate biological and physicochemical phenomena at the atomic scale. This methodology not only informs physical experimentation but also expedites the drug discovery and development phases. BIOVIA Discovery Studio integrates more than three decades of peer-reviewed research with cutting-edge in silico methodologies, including molecular mechanics, free energy assessments, and biotherapeutics developability, all within a unified framework. By equipping researchers with a comprehensive suite of tools, it facilitates a deeper examination of protein chemistry, thereby accelerating the discovery of both small and large molecule therapeutics, from Target Identification all the way through to Lead Optimization. Ultimately, this synergy of research and technology underscores the vital role of innovative tools in transforming biopharmaceutical advancements.

Since its inception in 1985, ChemDraw® solutions have delivered exceptional features and integrations that allow users to swiftly convert their concepts and sketches into impressive publications. ChemOffice+ Cloud serves as a comprehensive suite for chemistry communication, transforming chemical illustrations into valuable knowledge by streamlining the management, reporting, and presentation of chemistry research. This powerful suite is specifically designed to enhance and expedite communication within the field of chemistry. Building upon the foundation of ChemDraw Professional, ChemOffice+ Cloud offers a wide range of advanced tools that support scientific inquiry and collaboration. The once tedious process of drafting reports for chemical research is now significantly more efficient thanks to ChemOffice+ Cloud. With its robust capabilities for searching, reusing, selecting, and organizing chemical structures and data, chemists can effortlessly create polished PowerPoint presentations and manuscripts, making their work more accessible and impactful. This transformation not only saves time but also elevates the overall quality of research dissemination in the scientific community.

BIOVIA COSMO-RS serves as an extensive toolkit for modeling and forecasting fluid phase characteristics, which empowers professionals such as chemical engineers, chemists, formulation experts, and materials scientists to innovate and develop solutions more rapidly and effectively than relying solely on traditional testing and experimentation methods, thereby enhancing innovation while minimizing costs. The simulations conducted using COSMO-RS are grounded in a solid scientific framework, guaranteeing dependable predictions across the entire spectrum of liquid-state chemistry. By employing a first-principle methodology, it is capable of forecasting the properties of new compounds that have yet to be synthesized, pushing the boundaries of known chemical territory. The team behind BIOVIA consists of the original creators of COSMO-RS, providing prompt assistance and unparalleled expertise to tackle even the most complex challenges in solution thermodynamics. Additionally, the primary advantages encompass a solid scientific basis that merges quantum chemistry with thermodynamics to assure both accuracy and reliability, fostering a deeper understanding of fluid behaviors in various contexts. This comprehensive approach not only streamlines the research process but also opens up new avenues for exploration within the field.

Dotmatics is the global leader in R&D scientific software that connects science, data, and decision-making. More than 2 million scientists and 10,000 customers trust Dotmatics to accelerate research and help make the world a healthier, cleaner, and safer place to live.

Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.

Our advanced battery analytics platform delivers state-of-the-art solutions for monitoring, analyzing, and optimizing battery performance. By utilizing a variety of machine learning techniques and battery-specific algorithms, we ensure accurate results across diverse scenarios. The platform features an API that allows for seamless integration with third-party applications, such as fleet management systems. Instead of relying on guesswork, laboratory experiments, and cumbersome manual data management, users can conduct virtual testing and enjoy automated handling of lab data. The model library enables users to effectively test battery cells in a virtual environment, further enhancing the development process. Our data management software solutions also facilitate the efficient organization of lab data, allowing for better decision-making. By utilizing field data analytics, you can optimize your development efforts. The TWAICE battery model library grants access to a wide array of high-fidelity electrical, thermal, and aging models of the latest lithium-ion battery cells available on the market today, ensuring that you have the most accurate and up-to-date resources for your projects. This comprehensive approach not only streamlines the research and development process but also significantly accelerates innovation in battery technology.

AIDDISON™ is an innovative drug discovery software that harnesses the capabilities of artificial intelligence (AI), machine learning (ML), and advanced 3D computer-aided drug design (CADD) techniques, serving as an essential resource for medicinal chemistry applications. This comprehensive platform streamlines both ligand-based and structure-based drug design, effectively merging all components necessary for virtual screening while also facilitating in-silico lead discovery and optimization processes. By leveraging these cutting-edge technologies, AIDDISON™ significantly enhances the efficiency and effectiveness of the drug development pipeline.

ChemCopilot is an innovative platform that harnesses the power of artificial intelligence to revolutionize the formulation of chemicals and the management of their product lifecycles, catering to the needs of scientists, engineers, and research and development teams. By integrating specialized chemistry knowledge with regulatory information, simulation tools, and immediate insights, it streamlines the design, testing, optimization, and management of chemical products and processes. The platform automates the validation of product labels, compliance with ingredient restrictions, and the accuracy of safety data sheets in accordance with international regulations, effectively removing the need for cumbersome spreadsheets and manual checks while offering audit trails and real-time alerts to ensure regulatory compliance. Furthermore, ChemCopilot enhances the pace of innovation by simulating chemical reactions, molecular interactions, and operational processes to forecast formulation effectiveness and results in ways that conventional tools are unable to achieve. It also seamlessly incorporates real-time data from both laboratory and industrial environments, empowering teams to make informed, data-driven decisions that lead to better outcomes. This comprehensive approach not only optimizes workflows but also facilitates a more agile response to changing market demands and regulatory landscapes.

We combine clinical and experimental data through machine learning techniques to explore human disease biology and promote the development of precision medicine. Our innovative Contingent AI™ technology comprehends the intricate relationships present in the data, yielding advanced insights. To combat data bias, we refine our machine learning models based on decisions made during the pre-processing and feature engineering phases. We utilize zebrafish, cellular, and various phenotypic animal models to test and confirm in silico predictions through in vivo experiments, along with genetic modifications conducted both in vitro and in vivo to enhance translation. By employing active learning and computer vision on validated models that focus on cardiac, central nervous system, and rare disorders, we swiftly integrate new data into our machine learning frameworks, allowing for continuous improvement and adaptation in our methodologies. This iterative process not only enhances the accuracy of our predictions but also enables us to stay at the forefront of research in precision medicine.

Site-Identification by Ligand Competitive Saturation (SILCS) produces three-dimensional maps, known as FragMaps, that illustrate how different chemical functional groups interact with a specific target molecule. By revealing the complexities of molecular dynamics, SILCS offers tools that enhance the optimization of ligand scaffolds through both qualitative and quantitative insights into binding pockets, thereby streamlining the drug design process. This approach employs a range of small molecule probes, each featuring diverse functional groups, alongside explicit solvent modeling and accommodating the flexibility of the target molecule to effectively map protein targets. Furthermore, the technique allows researchers to visualize advantageous interactions with the target macromolecule. With these insights, scientists can strategically design improved ligands with functional groups situated in optimal positions for enhanced efficacy. The innovative nature of SILCS represents a significant advancement in the field of medicinal chemistry.

InSilicoTrials.com is an online platform that offers a user-friendly environment for computational modeling and simulation, featuring a range of integrated, easy-to-navigate in silico tools. It primarily serves professionals in the medical device and pharmaceutical industries. The in silico tools designed for medical devices facilitate computational testing across various biomedical fields, including radiology, orthopedics, and cardiovascular health, during the stages of product design, development, and validation. For the pharmaceutical industry, the platform grants access to in silico tools that support all phases of drug discovery and development across diverse therapeutic areas. We have developed a unique cloud-based platform grounded in crowdscience principles, allowing users to efficiently utilize validated models and reduce their R&D expenses. Additionally, users can explore a continuously expanding catalog of models available for use on a pay-per-use basis, ensuring flexibility and accessibility for their research needs.

BioNeMo is a cloud service and framework for drug discovery that leverages AI, built on NVIDIA NeMo Megatron, which enables the training and deployment of large-scale biomolecular transformer models. This service features pre-trained large language models (LLMs) and offers comprehensive support for standard file formats related to proteins, DNA, RNA, and chemistry, including data loaders for SMILES molecular structures and FASTA sequences for amino acids and nucleotides. Additionally, users can download the BioNeMo framework for use on their own systems. Among the tools provided are ESM-1 and ProtT5, both transformer-based protein language models that facilitate the generation of learned embeddings for predicting protein structures and properties. Furthermore, the BioNeMo service will include OpenFold, an advanced deep learning model designed for predicting the 3D structures of novel protein sequences, enhancing its utility for researchers in the field. This comprehensive offering positions BioNeMo as a pivotal resource in modern drug discovery efforts.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

Founded in 2000, VeraChem LLC aims to enhance the field of computer-aided drug discovery and molecular design by creating advanced computational chemistry techniques that merge innovative basic science with practical applications in research. A key aspect of the company's strategy for product development lies in delivering efficient, high-performance software solutions along with extensive user support. Among the current capabilities of VeraChem's software are predictions for protein-ligand and host-guest binding affinities, rapid and precise calculations of partial atomic charges for drug-like molecules, and the computation of energies and forces utilizing widely-used empirical force fields. Additionally, the software features automatic generation of alternate resonance forms for drug-like compounds, a robust conformational search enabled by the Tork algorithm, and the automatic identification of topological and three-dimensional molecular symmetries. The modular code base of VeraChem’s software packages allows for flexibility and adaptability in meeting diverse research needs, ensuring that users can leverage these tools effectively for their specific applications.

Predict absorption distribution metabolism and excretion properties from chemical structure. This collection of high-quality calculations for pharmacokinetic properties can be used to support high-throughput screening of libraries. It also provides insight into pharmacological effects and can help ensure that products are safe for humans.

BIOVIA TURBOMOLE is an advanced software package for quantum chemistry that specializes in ab initio electronic structure calculations for a variety of systems, including molecules, clusters, periodic structures, and solutions. Originally developed at the University of Karlsruhe and Forschungszentrum Karlsruhe GmbH, the package is currently managed by TURBOMOLE GmbH, which has expanded its capabilities to include a wide range of computational methods such as density functional theory (DFT), Møller–Plesset perturbation theory, coupled-cluster techniques, and GW-Bethe–Salpeter approaches. It stands out for its ability to provide precise predictions related to chemical reactions, spectroscopy, and simulations of optical devices. Key features include optimization of reaction pathways, searches for transition states, and the modeling of solvation effects through COSMO-RS. Additionally, its spectroscopic tools cover various techniques such as IR, Raman, VCD, UV-Vis, and vibronic spectra, while simulations of optical properties are enhanced by sophisticated methods for spin-orbit coupling and relativistic all-electron calculations. This powerful software thus serves as an essential resource for researchers aiming to explore complex chemical systems and their properties.

Makya stands out as the pioneering user-centric SaaS platform dedicated to AI-enhanced de novo drug design, particularly emphasizing Multi-Parametric Optimization (MPO). This innovative tool empowers users to create novel and easily synthesize compounds based on a multi-objective framework, achieving unprecedented levels of speed, efficiency, and variety. Makya incorporates a range of generative algorithms tailored to various stages of drug development, from hit discovery to lead optimization; it includes a fine-tuning generator for pinpointing ideal solutions within your specified chemical landscape, a novelty generator designed to explore fresh concepts for re-scaffolding and hit discovery, and a forward generator to create a targeted library of compounds that can be readily synthesized from commercially available starting materials. The recently introduced Makya 3D module significantly improves both the user interface and the scientific capabilities of the platform. With a comprehensive array of 3D modeling functionalities available for both ligand-based and structure-based approaches, Makya 3D allows for the calculation of 3D scores, which can be seamlessly utilized to guide compound generation within the platform. This integration not only enhances the design process but also offers researchers deeper insights into their molecular designs.

LiveDesign serves as an integrated informatics solution that empowers teams to accelerate their drug discovery initiatives through collaborative design, experimentation, analysis, tracking, and reporting on a unified platform. It allows for the collection of innovative ideas alongside experimental and modeling data seamlessly. Users can develop and archive new virtual compounds within a centralized repository, assess them with sophisticated models, and prioritize the most promising designs. By merging biological data and model outputs from various corporate databases, the platform leverages advanced cheminformatics to provide a comprehensive analysis of all information simultaneously, facilitating quicker compound development. The platform employs cutting-edge physics-based methodologies along with machine learning to enhance prediction accuracy significantly. Teams can collaborate in real-time, regardless of location, enabling them to share concepts, conduct tests, make revisions, and progress chemical series while maintaining a clear record of their work. This not only fosters innovation but also ensures that projects remain organized and efficient throughout the drug discovery process.

Calculate Abraham Solvation Parameters, and other solvation-related properties for solutes, directly from the chemical structure

Osium AI is an advanced software platform that harnesses artificial intelligence to assist industry leaders in speeding up the creation of sustainable, high-performance materials and chemicals. Utilizing an innovative technology founded on over ten years of expertise and numerous AI patents, Osium AI provides a comprehensive solution that addresses all phases of the materials and chemicals development process, including formulation, characterization, scale-up, and manufacturing. This platform empowers users to swiftly predict any material or chemical property within seconds, create optimal research and development experiment plans, and quickly analyze material characteristics and flaws. Additionally, it allows for the optimization of current processes, leading to reduced costs, improved material properties, and lower CO₂ emissions. With its adaptable software, Osium AI is equipped to support a wide range of R&D projects while accommodating the ever-changing demands of the industry. Overall, the platform stands out as a crucial tool for enhancing innovation in materials science.

Business intelligence in the global biopharmaceutical sector focuses on drug patent dynamics and the entry of generics. It is essential to forecast future budget needs and proactively seek out generic alternatives. Analyzing the achievements of past patent challengers provides insights into the competitive landscape and informs research directions. This analysis plays a crucial role in guiding portfolio management strategies for upcoming drug development projects. Additionally, anticipating the expiration of patents on branded drugs, pinpointing potential generic suppliers, and managing branded drug inventory effectively are vital. Furthermore, acquiring detailed formulation and manufacturing data helps in identifying key formulators, repackagers, and relabelers to streamline operations and enhance market positioning. Understanding these elements can significantly bolster strategic decision-making in the biopharmaceutical industry.

alvaModel is an advanced software application designed for the construction, validation, comparison, and implementation of QSAR and QSPR models. It excels in supporting both regression and classification tasks through the use of molecular descriptors and fingerprints, emphasizing transparency, interpretability, and scientific rigor in its models. This software offers a variety of data splitting techniques, variable selection approaches, and modeling algorithms, as well as thorough internal and external validation methods. Additionally, alvaModel includes diagnostic visualizations, applicability domain evaluations, and tools for model comparison, which aid users in pinpointing reliable and predictive modeling solutions. Crafted in accordance with the highest standards of chemometrics, alvaModel promotes the creation of interpretable models that align with OECD guidelines for QSAR validation, making it ideal for both research and regulatory uses. Its user-friendly graphical interface walks users through the entire modeling process while providing comprehensive control over every aspect of the modeling journey, ensuring a seamless experience. Ultimately, alvaModel stands out as a valuable asset for chemists and researchers aiming to enhance their modeling capabilities.

We have established ourselves as frontrunners in the fields of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology, a status achieved through the achievements our clients have experienced while partnering with us. Leveraging over two decades of expertise, our skilled team excels at transforming complex scientific concepts into accessible software solutions, while also offering specialized consulting services that bolster drug discovery, clinical development research, and regulatory submission processes. Our dedication to client success drives our continuous improvement and innovation in these critical areas.

alvaDesc is a cheminformatics tool designed for the computation and examination of molecular descriptors, fingerprints, and structural patterns, catering to QSAR, QSPR, read-across, and machine learning needs. It is capable of calculating over 5,000 molecular descriptors across various dimensions (0D–3D), which encompass constitutional, topological, geometrical, electronic, physicochemical, and fragment-based categories. In addition, the software produces molecular fingerprints and structural pattern counts that facilitate similarity analysis, clustering, and classification tasks. It comes equipped with integrated tools that allow for descriptor filtering and correlation analysis, ensuring that the modeling process is both robust and reproducible. Furthermore, alvaDesc offers seamless integration with KNIME and Python, making it easy to link with external data analysis and machine learning workflows. Its widespread use in both academic and industrial research is bolstered by comprehensive documentation and an array of scientific publications, which contribute to its reputation as a reliable resource in the field. Moreover, users appreciate its user-friendly interface that enhances the overall experience while conducting complex cheminformatics tasks.

Avogadro serves as a sophisticated molecular editor and visualizer that operates across multiple platforms, catering to fields such as computational chemistry, molecular modeling, bioinformatics, and materials science. With its ability to provide flexible, high-quality rendering alongside a robust plugin architecture, it enhances user experience significantly. This free, open-source tool is compatible with Mac, Windows, and Linux, making it accessible to a wide range of users in scientific disciplines. Its design emphasizes not only functionality but also adaptability to various research needs.

alvaMolecule serves as a no-code cheminformatics platform designed to visualize, curate, and standardize molecular datasets in preparation for analysis. It accommodates popular molecular formats, including SMILES and SDF/MOL2, allowing users to navigate through collections in either grid or spreadsheet formats, with automatic import of relevant data. This tool ensures structure verification and standardization via pre-set standardizers and customizable SMIRKS rules, facilitates the identification and management of duplicates, and provides scaffold analysis for summarizing fundamental frameworks. Additionally, it features integrated filters and charting options that allow sorting based on substructures, calculated molecular descriptors, and physicochemical properties. alvaMolecule is capable of calculating around 88 structural and physicochemical properties, which encompass drug-like and lead-like scores such as LogP, TPSA, and the Lipinski alert index, ultimately assisting users in generating high-quality datasets for QSAR/QSPR modeling, descriptor calculations, and virtual screening processes. Furthermore, its user-friendly interface ensures that researchers, regardless of their coding expertise, can easily navigate and utilize the tool to enhance their cheminformatics tasks effectively.

Chemical Computing Group (CCG) is well-known for its dedication to collaborative scientific assistance. Operating from locations across North America, Europe, and Asia, our team, comprised of PhD-level scientists, partners closely with clients to deliver personalized support, practical training, and expert scientific guidance on a diverse array of projects. In addition to this, CCG is committed to the ongoing development of innovative technologies, leveraging the expertise of mathematicians, scientists, and software engineers while also engaging in scientific partnerships with our customers to enhance research outcomes. This collaborative approach not only improves client satisfaction but also fosters a culture of innovation within the organization.

3decision® serves as a cloud-based repository for protein structures, focusing on efficient management of structural data and offering sophisticated analytics to support teams involved in the discovery of small molecules and biologics, thereby expediting the process of structure-based drug design. The platform consolidates and standardizes both experimental and computational protein structures sourced from publicly available databases such as RCSB PDB and AlphaFoldDB, in addition to proprietary datasets, and accommodates formats like PDBx/mmCIF and ModelCIF. This comprehensive approach guarantees seamless access to a variety of structural formats including X-Ray, NMR, cryo-EM, and modeled structures, thereby promoting collaboration and bolstering research initiatives. In addition to its storage capabilities, 3decision® enhances each entry with valuable metadata and sequence information, which encompasses details on protein-ligand interactions, antibody annotations, and specifics about binding sites. Equipped with advanced analytical instruments, the platform is capable of pinpointing druggable sites, evaluating off-target risks, and facilitating comparisons of binding sites, which collectively transform extensive structural datasets into practical insights that can drive research forward. Furthermore, its cloud-based architecture fosters enhanced collaboration among research teams, making it easier for scientists to share findings and insights, ultimately leading to more innovative approaches in drug discovery and development.

Our Next Energy is at the forefront of creating a sustainable electric future by developing innovative energy storage technologies that significantly enhance global access to clean power. Established in July 2020 by industry visionaries, Our Next Energy, Inc. leverages years of collective expertise to expedite the transition to electrification. The company has successfully showcased its Gemini 001 battery in an electric vehicle, which remarkably traveled 752 miles without needing a recharge, marking a revolutionary advancement in electric vehicle capabilities that meets the range demands of all drivers. The advanced battery features a capacity of 203.7 KWh and boasts an impressive energy density of 416 Wh/L. In addition, the Aries™ battery system surpasses its leading counterparts in overall system-level energy density. Utilizing a safe and sustainable lithium iron phosphate (LFP) cathode chemistry, Aries™ mitigates risks of thermal runaway while providing a flexible architecture that can be tailored for both series and parallel configurations, ensuring adaptability for various applications. This commitment to innovation not only positions Our Next Energy as a leader in the energy sector but also sets the stage for a more electrified and sustainable future.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

Evaluate formulations for sourcing and product development by utilizing our comprehensive 23 toxicological endpoint system, which enables the early detection of potential problems and the identification of safer alternatives. Gain insight into your organization's chemical footprint and streamline compliance and certification processes efficiently. Our user-friendly interface simplifies the collection of data, list-screening, and chemical hazard evaluations. Leverage the extensive Safer Chemistry Knowledge Base, featuring over 4,000 Verified Chemical Hazard Assessments conducted by Scivera’s certified toxicologists. Create a customized plan tailored to your specific needs and financial constraints. Whether you are a supplier or a brand, rest assured that you can submit or receive chemical reports with redacted details, ensuring the protection of intellectual property while still delivering essential safety information regarding chemicals. This dual focus on safety and confidentiality helps foster trust and transparency in the industry.

NobleAI empowers businesses to hasten the creation of high-performance, eco-friendly, and responsibly sourced chemical and material products. We at NobleAI hold the conviction that advancements in materials science and chemistry are crucial for fostering a sustainable future, with AI playing a pivotal role in realising this vision. Our science-driven AI represents a robust integration of innovative artificial intelligence methods and comprehensive scientific knowledge, tailored specifically for product development. By merging data-informed insights with scientifically validated design, we achieve significantly enhanced accuracy while requiring considerably less data and shorter training durations. This approach not only uncovers deeper insights but also promotes greater transparency, interpretability, and adherence to scientific principles, ultimately leading to more informed decision-making in material innovation. As we continue to refine our methods, our commitment to sustainability remains at the forefront of our mission.

Alchemy is a SaaS company focused on transforming the $1 trillion specialty chemicals sector. By streamlining formula development and commercialization, Alchemy enables specialty chemicals firms to enhance customer responsiveness and boost revenue. With its innovative Chemistry Acceleration Software, clients can expand lab capabilities, expedite chemical innovations, and increase sales figures. Alchemy enhances the entire product development journey, from initial concepts to final chemistry, while also elevating service delivery for companies in the chemicals and materials space. Whether engaged in fundamental research, launching new products, or optimizing existing offerings for customers, Alchemy effectively accelerates laboratory, sales, and service operations. This results in a faster route to revenue for new product development, reduced laboratory costs per sale, and improved customer engagement. Alchemy's specialized software is tailored to expedite the development of chemistry, sales, and service processes, making it a vital partner in the industry. As a result, organizations can navigate market challenges with greater agility and efficiency.

Cytel stands out as a prominent global innovator in software for clinical trial design, biometrics, and advanced analytics, focusing on maximizing the efficiency of clinical trials while aiding pharmaceutical companies in harnessing the full scope of both clinical and real-world data. Established in 1987 by renowned statisticians Cyrus Mehta and Nitin Patel, Cytel has consistently been a leader in adaptive clinical trial technology and the field of biostatistics. Its software solutions, notably the East Horizon platform, facilitate accurate trial design and simulation, employing adaptive and Bayesian methodologies to enhance protocols and expedite the drug development process. The East Horizon platform serves as a comprehensive integration of Cytel's reliable software offerings, featuring R integration that significantly improves trial design functions. Furthermore, Cytel provides the Xact software suite, which is an all-encompassing toolkit designed for statistical analysis of small datasets, including those with sparse and missing data. By continuously innovating and expanding its product offerings, Cytel remains committed to providing cutting-edge solutions that meet the evolving needs of clinical research.

BIOVIA solutions foster an unparalleled environment for scientific management, enabling organizations focused on science to develop and interlink innovations in biology, chemistry, and materials to enhance our quality of life. The leading BIOVIA portfolio emphasizes the seamless integration of diverse scientific disciplines, experimental workflows, and information needs throughout the entire spectrum of research, development, quality assurance, quality control, and manufacturing. It boasts capabilities spanning Scientific Informatics, Molecular Modeling and Simulation, Data Science, Laboratory Informatics, Formulation Design, BioPharma Quality and Compliance, as well as Manufacturing Analytics. BIOVIA is dedicated to accelerating innovation, boosting productivity, enhancing quality and compliance, lowering costs, and expediting product development for clients across various sectors. Additionally, it plays a crucial role in managing and unifying scientific innovation processes and information throughout the entire product lifecycle, ensuring a comprehensive approach to scientific advancement.

Eatron's Intelligent Software Layer (ISL) represents an innovative approach aimed at maximizing the capabilities of batteries by improving their performance, increasing their longevity, and prioritizing safety. By utilizing our unique algorithms, we achieve remarkable State of Charge (SoC) accuracy of ±1%, which is significantly better than the industry standard of ±3%, while also ensuring a State of Health (SoH) accuracy of ±2% across the battery's lifespan, compared to the typical ±5%. This level of precision enables the extraction of optimal performance from batteries without sacrificing safety measures. Our patented method for forecasting Remaining Useful Life (RUL) integrates a comprehensive knowledge of battery chemistries with cutting-edge machine learning and AI technologies, facilitating real-time life predictions based on actual usage patterns. Continuous monitoring of battery health allows us to respond to changes within the pack, potentially prolonging operational life by as much as 25%. Furthermore, safety remains a top priority; our AI diagnostic tools can foresee cell failures weeks in advance with an impressive accuracy rate of 90%, ensuring reliable operation and peace of mind for users. This holistic approach not only enhances battery efficiency but also sets a new standard in the field of battery management technology.

MolPad seamlessly incorporates an interactive chemistry sketching tool into various online educational platforms. It allows educators to create open-ended questions regarding molecular structures and organic chemistry that extend beyond simply identifying correct answers. Explore how MolPad enhances online chemistry instruction through a low-code framework that facilitates the development of engaging content and intelligent assessments. Our platform has introduced multiple solutions for the intuitive drawing of structural formulas, allowing students to engage with concepts such as chemical nomenclature, functional groups, and Lewis structures in a digital setting. By offering targeted feedback based on individual mistakes, students can achieve a deeper understanding compared to traditional multiple-choice formats, ultimately fostering a richer learning experience in chemistry. Additionally, this interactive approach encourages students to think critically and creatively about chemical concepts.

Introducing the next evolution in hardware wallets. With airgapped security and a fully open-source design, Passport is proudly assembled in the USA. This device maintains complete isolation from external connections, lacking both USB data transfer and wireless communication. Instead, it utilizes a camera paired with QR codes for its communication needs, ensuring robust airgapped security while remaining user-friendly. Equipped with a 1200 mAh Lithium Ion battery that follows a standard form factor, the battery can be easily removed and replaced as necessary. To recharge the battery, Passport features a power-only USB-C port that does not allow data transmission, reinforcing its airgapped security approach. The latest Passport Batch 2 boasts a high-resolution, color IPS display that is bonded to ultra-durable cover glass. This vibrant screen simplifies QR code scanning significantly, while the tough cover glass offers protection against scratches and other potential damage, all while maintaining a crystal-clear viewing experience. Not only does the Passport prioritize security, but it also emphasizes convenience and durability for its users.

Chemia is an innovative ELN platform that operates in the cloud and via browsers, specifically tailored by scientists for their peers. This platform facilitates the management, assignment, monitoring, and documentation of all research and development endeavors from a single intuitive dashboard. It transforms your R&D processes into entirely paperless operations, drastically improving efficiency by saving approximately one hour per scientist through enhanced cross-functional collaboration. Additionally, Chemia ensures that your lab remains audit-ready and manages data with utmost precision. The platform allows for quick retrieval, efficient searching, comparative studies, and reconfigurability, which in turn supports faster and more informed decision-making. Furthermore, Chemia includes an inventory management system that systematically organizes, maintains, and schedules essential information regarding chemicals and equipment utilized in the laboratory. It also offers detailed logs for equipment usage, maintenance, and calibration, which contribute to optimal lab management and productivity. Lastly, the system provides established protocols to ensure compliance with regulatory standards, thereby reinforcing operational integrity.